ReachRxResearch
Home
Research
Sign Up
Compartment-specific PPARδ activity controls the outcome of cancer–immune cell competition and immunotherapy efficacy
Back to Research Hub
  1. Home
  2. Research Hub
  3. Compartment-specific PPARδ activity cont…

Compartment-specific PPARδ activity controls the outcome of cancer–immune cell competition and immunotherapy efficacy

Nature Immunology·October 14Open Access
ImmunologyPractice changingBreast CancerColorectal CancerMelanomaMicrosatellite Stable Metastatic Colorectal CancerPreclinical Animal Study With Human Ex Vivo ValidationAdoptive Cell TherapyCAR-T Cell TherapyImmune Checkpoint BlockadePPAR AgonistAdultAnti-CTLA-4Anti-PD-1GW501516

Summary

View source

What was studied

Whether PPARδ activation in immune cells versus cancer cells differentially controls antitumor immunity and immunotherapy efficacy, studied using compartment-specific genetic gain- and loss-of-function mouse models, human patient-derived organoid co-cultures, and human CAR-T cell systems across microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer and other tumor types.

Key findings

Immune-specific PPARδ activation suppressed tumor growth across MSI and MSS models, overriding pro-tumorigenic effects of cancer-cell PPARδ; in mice bearing MSS metastatic CRC (AKPS), adoptive transfer of PPARδ-activated CD8+ T cells plus anti-PD-1 led to 50% complete tumor rejection, significant metastasis reduction (2/13 vs 8/11 in controls), and improved survival with combined checkpoint blockade (p=0.0121). Pharmacological (GW501516) or genetic PPARδ activation also enhanced human EGFR- and HER-2-targeting CAR-T cell cytotoxicity in vitro and in vivo.

Study limitations

All in vivo findings are in preclinical mouse models; the VP16/VP64 constitutively active fusion does not fully replicate native ligand-dependent PPARδ biology and may not capture transrepression effects. Adoptive transfer experiments required lymphodepleting irradiation, which could confound outcomes. Long-term safety of immune-specific PPARδ activation was not assessed beyond the observation period, and no sex-stratified or clinical human trial data are presented.

Clinical implications

Selectively activating PPARδ in immune cells—rather than systemically—could enhance CD8+ T cell fitness and sensitize immunotherapy-resistant MSS colorectal cancer to checkpoint blockade; this principle may guide development of metabolic preconditioning strategies for adoptive cell therapies such as CAR-T cells in solid tumors.

Caveats

  • All efficacy findings are from mouse tumor models or ex vivo human co-culture assays; no clinical trial data are available
  • No sample size was formally pre-determined by power calculation; group sizes were chosen by convention from prior publications
  • The constitutively active VP16/VP64-PPARδ fusion used in genetic models does not equivalently replicate pharmacological PPARδ activation, limiting direct translation of genetic findings to drug use
Show all 4
  • The PPARδ agonist GW501516 (Cardarine) has prior safety concerns including potential pro-tumorigenic effects in cancer cells—compartment-specific delivery would be essential for any clinical translation

Related Questions

Explore related topics

PPARδ agonist GW501516 CD8 T cell metabolic reprogramming immunotherapymicrosatellite stable colorectal cancer checkpoint blockade resistance strategiesCAR-T cell fatty acid oxidation Cpt1a metabolic fitness solid tumors

Publication Details

Year
2026
Journal
Nature Immunology
Source
View article
Keep scrolling
More content below.
Up Next